Literature DB >> 2140294

Percutaneous transluminal renal angioplasty: initial results and long-term follow-up in 202 patients.

A L Baert1, G Wilms, A Amery, J Vermylen, R Suy.   

Abstract

Percutaneous transluminal renal angioplasty was performed in 202 patients with 250 stenoses. The procedure was successful in 201 of 250 (83%). Results were better for postostial atherosclerotic lesions (94%), fibromuscular lesions (83%), and transplant kidneys (71%) than for ostial atherosclerotic lesions (29%). Of all the patients, 61% had reduced blood pressures following the procedure, with cure (diastolic blood pressure less than or equal to 90 mm Hg) in 31% of the patients. Cure rate with a mean follow-up of 25.8 +/- 19.4 months was 21% in bilateral atheromatous lesions, 30% in unilateral atheromatosis, 65% in unilateral fibromuscular disease, and 40% in bilateral fibromuscular dysplasia. Of the transplanted patients, 60% were cured. Complications occurred in 23 (11%) of the patients. Recurrence of stenoses occurred in 16 lesions (8%), 80% within the first year after the procedure.

Entities:  

Mesh:

Year:  1990        PMID: 2140294     DOI: 10.1007/bf02576933

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  47 in total

Review 1.  Techniques of renal angioplasty.

Authors:  C J Tegtmeyer; T A Sos
Journal:  Radiology       Date:  1986-12       Impact factor: 11.105

2.  Nonsurgical treatment of severe hypertension due to renal-artery intimal fibroplasia by percutaneous transluminal angioplasty.

Authors:  V G Millan; W E Mast; N E Madias
Journal:  N Engl J Med       Date:  1979-06-14       Impact factor: 91.245

3.  Cooperative study of renovascular hypertension. Demographic analysis of the study.

Authors:  M H Maxwell; K H Bleifer; S S Franklin; P D Varady
Journal:  JAMA       Date:  1972-05-29       Impact factor: 56.272

4.  Clinical experience with percutaneous transluminal angioplasty (PTA) of stenotic renal arteries.

Authors:  D E Schwarten; H Y Yune; E C Klatte; C E Grim; M H Weinberger
Journal:  Radiology       Date:  1980-06       Impact factor: 11.105

5.  Intimal fibromuscular dysplasia and Takayasu arteritis: delayed response to percutaneous transluminal renal angioplasty.

Authors:  M F Srur; T A Sos; S Saddekni; D J Cohn; G Rozenblit; E B Wetter
Journal:  Radiology       Date:  1985-12       Impact factor: 11.105

6.  Percutaneous transluminal renal angioplasty. A potentially effective treatment for preservation of renal function.

Authors:  N E Madias; O J Kwon; V G Millan
Journal:  Arch Intern Med       Date:  1982-04

7.  Renovascular occlusive disease. Results of operative treatment.

Authors:  J H Foster; M H Maxwell; S S Franklin; K H Bleifer; O H Trippel; O C Julian; P T DeCamp; P T Varady
Journal:  JAMA       Date:  1975-03-10       Impact factor: 56.272

8.  Renal artery angioplasty: increased technical success and decreased complications in the second 100 patients.

Authors:  L G Martin; W J Casarella; J P Alspaugh; V P Chuang
Journal:  Radiology       Date:  1986-06       Impact factor: 11.105

9.  Lasting improvement of renovascular hypertension by transluminal dilatation of atherosclerotic and nonatherosclerotic renal artery stenoses. A follow-up study.

Authors:  F Mahler; P Probst; M Haertel; P Weidmann; A Krneta
Journal:  Circulation       Date:  1982-03       Impact factor: 29.690

10.  Renal vascular hypertension. Surgery vs. dilation.

Authors:  C E Grim; H Y Yune; J P Donohue; M H Weinberger; R Dilley; E C Klatte
Journal:  Nephron       Date:  1986       Impact factor: 2.847

View more
  2 in total

1.  Renal vein injury during percutaneous transluminal renal angioplasty in nonspecific aortoarteritis.

Authors:  S Sharma; S Arya; S N Mehta; K K Talwar; M Rajani
Journal:  Cardiovasc Intervent Radiol       Date:  1993 Mar-Apr       Impact factor: 2.740

Review 2.  Drug-eluting stents in renal artery stenosis.

Authors:  M Zähringer; P M T Pattynama; A Talen; M Sapoval
Journal:  Eur Radiol       Date:  2007-10-11       Impact factor: 5.315

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.